Fluff Or Next Potential Discovery? FDA Wants Simpler Clinical Trials, But Not Telling Sponsors Endpoints Are Unnecessary

Some of the growing number of secondary and tertiary endpoints may not be needed, but also could fuel future products and advance science.

simplicity
Can the FDA encourage simpler clinical trials without squelching scientific research? • Source: Shutterstock

Podium policy on clinical trial simplification does not seem to be filtering down to the US Food and Drug Administration’s rank-and-file reviewing and approving the protocols.

So-called “fluff,” or unnecessary endpoints, continues to grow, making clinical trials much more complex and burdensome, agency officials said during...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D